Cedrene administration mitigates these effects in wild‐type mice but not in MOR23 knockout mice, highlighting the therapeutic potential of MOR23 activation in managing hepatic steatosis and its associated metabolic disturbances. This evidence concerns the gene OR10J5 and fatty liver disease.